Cv Sciences Financials
Cv Sciences (CVSI) reported $13.8M in revenue for fiscal year 2025, down 12.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
CV Sciences is becoming a leaner but smaller company, with margin repair driven mainly by overhead cuts.
Between FY2022 and FY2025, gross margin rose from34.3% to48.9% even as sales kept shrinking. SG&A reset from$12.1M to$7.6M did most of the work, so the move toward operating break-even came from a smaller cost base rather than a stronger revenue engine.
The balance sheet is inventory-heavy: FY2025 inventory was
Earnings quality was not the core issue: when expenses briefly aligned, profit and cash flow moved together, but that alignment did not persist. In FY2025, interest expense of
Financial Health Signals
Cv Sciences does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Cv Sciences scores -15.41, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($4.5M) relative to total liabilities ($5.5M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Cv Sciences passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
Cv Sciences reported a net loss of $958K while operations used $407K of cash. With neither figure positive, the ratio between the two carries no quality signal.
Cv Sciences reported an operating loss of $470K against $517K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Cv Sciences generated $13.8M in revenue in fiscal year 2025. This represents a decrease of 12.2% from the prior year.
Cv Sciences's EBITDA was -$278K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 85.0% from the prior year.
Cv Sciences reported -$958K in net income in fiscal year 2025. This represents an increase of 60.0% from the prior year.
Cash & Balance Sheet
Cv Sciences recorded an outflow of $516K in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 41.3% from the prior year.
Cv Sciences held $278K in cash against $387K in long-term debt as of fiscal year 2025, with $5.0M of liabilities due within a year.
Not reported for fiscal year 2025.
Margins & Returns
Cv Sciences's gross margin was 49.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 3.3 percentage points from the prior year.
Cv Sciences's operating margin was -3.4% in fiscal year 2025, reflecting core business profitability. This is up 10.5 percentage points from the prior year.
Cv Sciences's net profit margin was -7.0% in fiscal year 2025, showing the share of revenue converted to profit. This is up 8.3 percentage points from the prior year.
Cv Sciences's ROE was -65.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 68.1 percentage points from the prior year.
Capital Allocation
Cv Sciences invested $122K in research and development in fiscal year 2025. This represents an increase of 3.4% from the prior year.
Cv Sciences invested $109K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 505.6% from the prior year.
Not reported for fiscal year 2025.
CVSI Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.7M | $13.8M-12.2% | $15.7M-1.9% | $16.0M-1.2% | $16.2M-19.2% | $20.0M-17.9% | $24.4M-54.5% | $53.7M+11.3% | $48.2M+133.3% | $20.7M+87.0% | $11.1M-4.1% | $11.5M+13.1% | $10.2M+373.1% | $2.2M | $0 | N/A |
| Cost of Revenue | $6.5M | $7.0M-17.6% | $8.5M-4.3% | $8.9M-16.3% | $10.7M-6.8% | $11.4M-14.8% | $13.4M-27.9% | $18.6M+29.5% | $14.4M+132.1% | $6.2M+52.4% | $4.1M-15.3% | $4.8M+9.4% | $4.4M+398.3% | $880K | $0 | N/A |
| Gross Profit | $6.3M | $6.8M-5.8% | $7.2M+1.2% | $7.1M+27.7% | $5.5M-35.6% | $8.6M-21.7% | $11.0M-68.6% | $35.1M+3.6% | $33.9M+133.8% | $14.5M+107.1% | $7.0M+4.0% | $6.7M+16.0% | $5.8M+355.7% | $1.3M | $0 | N/A |
| R&D Expenses | $78K | $122K+3.4% | $118K-21.9% | $151K-50.8% | $307K-74.1% | $1.2M-59.7% | $2.9M-49.9% | $5.9M+211.8% | $1.9M+160.4% | $724K-37.5% | $1.2M-12.2% | $1.3M+32.1% | $999K+90.5% | $524K | $0 | N/A |
| SG&A Expenses | $7.2M | $7.6M-17.5% | $9.2M-5.2% | $9.7M-19.4% | $12.1M-53.3% | $25.9M-15.6% | $30.7M-34.0% | $46.5M+113.6% | $21.7M+34.3% | $16.2M+23.3% | $13.1M-24.4% | $17.4M+30.1% | $13.4M+464.5% | $2.4M | N/A | $88K |
| Operating Income | -$969K | -$470K+78.5% | -$2.2M-165.2% | $3.4M+149.1% | -$6.8M+62.9% | -$18.4M+18.4% | -$22.6M-31.0% | -$17.2M-268.2% | $10.2M+310.8% | -$4.9M+62.8% | -$13.1M-16.6% | -$11.2M-31.1% | -$8.6M-428.8% | -$1.6M | N/A | N/A |
| Interest Expense | $330K | $517K+143.9% | $212K | N/A | $600K+1478.9% | $38K+522.2% | -$9K-160.0% | $15K-90.2% | $153K-69.8% | $507K-53.3% | $1.1M+12.2% | $969K+57.4% | $615K+65.4% | $372K | N/A | $2K |
| Income Tax | $7K | $9K+212.5% | -$8K-33.3% | -$6K+87.2% | -$47K+46.0% | -$87K+72.6% | -$317K+48.5% | -$615K-761.3% | $93K+119.3% | -$482K | $0 | $0 | $0 | $0 | $0 | N/A |
| Net Income | -$2.0M | -$958K+60.0% | -$2.4M-177.2% | $3.1M+137.8% | -$8.2M+47.2% | -$15.6M+30.2% | -$22.3M-34.2% | -$16.6M-266.1% | $10.0M+304.2% | -$4.9M+65.4% | -$14.1M-15.6% | -$12.2M-832.4% | -$1.3M+43.0% | -$2.3M | N/A | -$90K |
| EPS (Diluted) | — | -$0.01 | -$0.01 | $0.02+128.6% | -$0.07+50.0% | -$0.14+36.4% | -$0.22-29.4% | -$0.17-288.9% | $0.09+250.0% | -$0.06 | N/A | N/A | N/A | N/A | N/A | N/A |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
CVSI Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $7.0M-12.2% | $7.9M-13.8% | $9.2M-27.8% | $12.7M-29.5% | $18.1M-41.0% | $30.6M-41.9% | $52.7M+42.8% | $36.9M+62.5% | $22.7M+22.1% | $18.6M-31.9% | $27.3M+25.6% | $21.7M+52.8% | $14.2M+3301994.7% | $431 | N/A |
| Current Assets | $5.1M-17.8% | $6.2M-21.4% | $7.9M-28.7% | $11.1M-21.5% | $14.2M-15.9% | $16.9M-47.9% | $32.4M+27.1% | $25.5M+220.9% | $7.9M+64.6% | $4.8M-70.9% | $16.6M-1.3% | $16.8M+108.6% | $8.1M+1869120.9% | $431-85.2% | $3K |
| Cash & Equivalents | $278K-38.8% | $454K-65.5% | $1.3M+115.5% | $611K-55.6% | $1.4M-65.8% | $4.0M-55.8% | $9.1M-28.2% | $12.7M+354.3% | $2.8M+164.0% | $1.1M+104.0% | $518K-77.5% | $2.3M+2.6% | $2.2M+520473.1% | $431-63.1% | $1K |
| Inventory | $4.1M-16.5% | $4.9M-13.4% | $5.7M-13.8% | $6.6M-23.9% | $8.6M-2.4% | $8.8M-11.3% | $10.0M+39.8% | $7.1M+152.6% | $2.8M-1.0% | $2.9M-79.8% | $14.1M+21.2% | $11.7M+371.7% | $2.5M | $0 | N/A |
| Accounts Receivable | $402K-23.0% | $522K+21.1% | $431K-43.7% | $766K-62.5% | $2.0M+81.3% | $1.1M-48.3% | $2.2M-34.8% | $3.3M+121.6% | $1.5M+318.1% | $360K-58.6% | $871K+208.3% | $282K-80.3% | $1.4M | $0 | N/A |
| Goodwill | $1.0M+4.5% | $971K+183.9% | $342K | $0 | $0-100.0% | $2.8M0.0% | $2.8M0.0% | $2.8M0.0% | $2.8M0.0% | $2.8M-40.0% | $4.6M+150.3% | $1.9M0.0% | $1.9M | $0 | N/A |
| Total Liabilities | $5.5M-10.4% | $6.1M-2.6% | $6.3M-53.4% | $13.5M-7.0% | $14.5M-25.2% | $19.4M-17.5% | $23.5M+246.9% | $6.8M+7.2% | $6.3M+17.6% | $5.4M+34.3% | $4.0M+503.3% | $665K-88.8% | $5.9M+1184944.0% | $500 | N/A |
| Current Liabilities | $5.0M-18.2% | $6.1M-0.1% | $6.1M-54.1% | $13.3M-7.9% | $14.5M+0.9% | $14.3M+8.6% | $13.2M+200.5% | $4.4M+31.7% | $3.3M+6.0% | $3.1M+28.4% | $2.5M+269.1% | $665K+57.3% | $423K+84425.0% | $500-98.8% | $41K |
| Long-Term Debt | $387K | $0 | N/A | N/A | $0-100.0% | $1.5M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $1.5M-18.2% | $1.8M-38.2% | $2.9M+473.6% | -$777K-121.9% | $3.5M-68.4% | $11.2M-61.5% | $29.1M-3.2% | $30.1M+83.8% | $16.4M+24.0% | $13.2M-43.3% | $23.3M+10.5% | $21.1M+153.7% | $8.3M+12038952.2% | -$69+99.8% | -$38K |
| Retained Earnings | -$87.9M-1.1% | -$87.0M-2.8% | -$84.6M+3.5% | -$87.7M-10.3% | -$79.5M-24.3% | -$63.9M-53.5% | -$41.6M-66.4% | -$25.0M+28.6% | -$35.0M-16.3% | -$30.1M-88.4% | -$16.0M-325.7% | -$3.8M-53.7% | -$2.4M-1595.0% | -$144K-46.3% | -$99K |
CVSI Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$492K | -$407K+52.7% | -$861K-138.2% | $2.3M+219.5% | -$1.9M+74.8% | -$7.5M-2.5% | -$7.3M-227.8% | -$2.2M-117.7% | $12.6M+247.4% | $3.6M+276.0% | -$2.1M+51.2% | -$4.2M+37.3% | -$6.7M-37.6% | -$4.9M | N/A | -$80K |
| Capital Expenditures | $30K | $109K+505.6% | $18K | $0 | $0-100.0% | $35K-96.7% | $1.1M-7.8% | $1.1M+28.4% | $893K+96.7% | $454K+2538.5% | $17K-84.8% | $114K-74.7% | $449K+98.2% | $227K | $0 | N/A |
| Free Cash Flow | -$522K | -$516K+41.3% | -$879K-139.0% | $2.3M+219.5% | -$1.9M+74.9% | -$7.5M+10.0% | -$8.4M-147.7% | -$3.4M-128.9% | $11.7M+269.1% | $3.2M+252.6% | -$2.1M+52.1% | -$4.3M+39.6% | -$7.2M-40.3% | -$5.1M | N/A | N/A |
| Investing Cash Flow | -$30K | -$109K-289.3% | -$28K+82.1% | -$156K | $0+100.0% | -$35K+96.7% | -$1.1M+7.8% | -$1.1M+7.8% | -$1.2M+37.8% | -$2.0M-334.6% | $853K | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | -$98K | $337K+953.1% | $32K+102.3% | -$1.4M-224.1% | $1.1M-74.3% | $4.4M+33.5% | $3.3M+6866.0% | $47K+104.0% | -$1.2M-1084.9% | $119K-93.2% | $1.7M | N/A | N/A | N/A | N/A | $50K |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
CVSI Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 49.0%+3.3pp | 45.6%+1.4pp | 44.3%+10.0pp | 34.3%-8.7pp | 43.0%-2.1pp | 45.1%-20.3pp | 65.3%-4.9pp | 70.2%+0.2pp | 70.1%+6.8pp | 63.3%+4.9pp | 58.4%+1.4pp | 57.0%-2.2pp | 59.1% | N/A | N/A |
| Operating Margin | -3.4%+10.5pp | -13.9%-34.9pp | 21.0%+63.2pp | -42.3%+49.8pp | -92.0%+0.5pp | -92.5%-60.4pp | -32.1%-53.3pp | 21.2%+44.7pp | -23.5% | -118.2% | -97.2%-13.3pp | -83.9%-8.9pp | -75.1% | N/A | N/A |
| Net Margin | -7.0%+8.3pp | -15.2%-34.6pp | 19.4%+70.1pp | -50.7%+26.9pp | -77.6%+13.6pp | -91.2%-60.3pp | -30.9%-51.7pp | 20.7%+44.4pp | -23.7% | -127.8% | -106.1% | -12.9% | -106.8% | N/A | N/A |
| Return on Equity | -65.3%+68.1pp | -133.4%-240.2pp | 106.8% | N/A | -439.0%-240.3pp | -198.8%-141.8pp | -57.0%-90.2pp | 33.2%+63.1pp | -29.9%+77.2pp | -107.1%-54.5pp | -52.5%-46.3pp | -6.2%+21.5pp | -27.7% | N/A | N/A |
| Return on Assets | -13.8%+16.4pp | -30.2%-63.9pp | 33.7%+98.2pp | -64.5%+21.6pp | -86.1%-13.3pp | -72.8%-41.2pp | -31.5%-58.6pp | 27.1%+48.7pp | -21.6%+54.5pp | -76.1%-31.2pp | -44.8%-38.8pp | -6.0%+10.1pp | -16.2% | N/A | N/A |
| Current Ratio | 1.030.0x | 1.02-0.3x | 1.30+0.5x | 0.84-0.1x | 0.98-0.2x | 1.18-1.3x | 2.45-3.3x | 5.80+3.4x | 2.38+0.8x | 1.53-5.2x | 6.76-18.5x | 25.29+6.2x | 19.06+18.2x | 0.86+0.8x | 0.07 |
| Debt-to-Equity | 0.26+0.3x | 0.00-2.2x | 2.17 | N/A | 0.00-0.1x | 0.13-0.7x | 0.81+0.6x | 0.23-0.2x | 0.390.0x | 0.41+0.2x | 0.17+0.1x | 0.03-0.7x | 0.71 | N/A | N/A |
| FCF Margin | -3.7%+1.9pp | -5.6%-19.7pp | 14.1%+25.7pp | -11.6%+25.9pp | -37.5%-3.3pp | -34.2%-27.9pp | -6.3%-30.5pp | 24.2%+8.9pp | 15.3%+34.0pp | -18.7%+18.8pp | -37.5%+32.8pp | -70.3% | -237.0% | N/A | N/A |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Cv Sciences Ranks
Frequently Asked Questions
What is Cv Sciences's annual revenue?
Cv Sciences (CVSI) reported $13.8M in total revenue for fiscal year 2025. This represents a -12.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Cv Sciences's revenue growing?
Cv Sciences (CVSI) revenue declined by 12.2% year-over-year, from $15.7M to $13.8M in fiscal year 2025.
Is Cv Sciences profitable?
No, Cv Sciences (CVSI) reported a net income of -$958K in fiscal year 2025, with a net profit margin of -7.0%.
What is Cv Sciences's EBITDA?
Cv Sciences (CVSI) had EBITDA of -$278K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Cv Sciences have?
As of fiscal year 2025, Cv Sciences (CVSI) had $278K in cash and equivalents against $387K in long-term debt.
What is Cv Sciences's gross margin?
Cv Sciences (CVSI) had a gross margin of 49.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Cv Sciences's operating margin?
Cv Sciences (CVSI) had an operating margin of -3.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Cv Sciences's net profit margin?
Cv Sciences (CVSI) had a net profit margin of -7.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Cv Sciences's return on equity (ROE)?
Cv Sciences (CVSI) has a return on equity of -65.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Cv Sciences's free cash flow?
Cv Sciences (CVSI) recorded an outflow of $516K in free cash flow during fiscal year 2025. This represents a 41.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Cv Sciences's operating cash flow?
Cv Sciences (CVSI) recorded an outflow of $407K in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Cv Sciences's total assets?
Cv Sciences (CVSI) had $7.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Cv Sciences's capital expenditures?
Cv Sciences (CVSI) invested $109K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Cv Sciences spend on research and development?
Cv Sciences (CVSI) invested $122K in research and development during fiscal year 2025.
What is Cv Sciences's current ratio?
Cv Sciences (CVSI) had a current ratio of 1.03 as of fiscal year 2025, which is considered adequate.
What is Cv Sciences's debt-to-equity ratio?
Cv Sciences (CVSI) had a debt-to-equity ratio of 0.26 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Cv Sciences's return on assets (ROA)?
Cv Sciences (CVSI) had a return on assets of -13.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Cv Sciences's cash runway?
Based on fiscal year 2025 data, Cv Sciences (CVSI) had $278K in cash against an annual operating cash burn of $407K. This gives an estimated cash runway of approximately 8 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Cv Sciences's Altman Z-Score?
Cv Sciences (CVSI) has an Altman Z-Score of -15.41, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Cv Sciences's Piotroski F-Score?
Cv Sciences (CVSI) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Cv Sciences's earnings high quality?
Cv Sciences (CVSI) reported a net loss of $958K while operations used $407K of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Cv Sciences cover its interest payments?
Cv Sciences (CVSI) reported an operating loss of $470K against $517K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.